PRDX4 and prostate cancer: Of note, MDA-MB-231 cells depleted of L-plastin and Peroxiredoxin 4 (PRDX4), another osteoclastogenic factor described also in prostate cancer cell PC3 (68), significantly reduced the osteolytic lesions in a murine model (66).